<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02229851</url>
  </required_header>
  <id_info>
    <org_study_id>NN8640-4054</org_study_id>
    <secondary_id>2013-002892-16</secondary_id>
    <secondary_id>U1111-1145-0211</secondary_id>
    <secondary_id>JapicCTI-152767</secondary_id>
    <nct_id>NCT02229851</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.</brief_title>
  <acronym>REAL 1</acronym>
  <official_title>A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly&#xD;
      dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin&#xD;
      (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone&#xD;
      deficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2014</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">April 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Truncal Fat Percentage (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Truncal fat percentage was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Truncal Fat Percentage (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Truncal fat percentage was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Truncal Fat Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Truncal fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Truncal Fat Mass (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Truncal fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Truncal Lean Body Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Truncal lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Truncal Lean Body Mass (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Truncal lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Fat Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Total fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Fat Mass (Week 87)</measure>
    <time_frame>Week -3, week 87</time_frame>
    <description>Change in total fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visceral Adipose Tissue (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visceral Adipose Tissue (Week 87)</measure>
    <time_frame>Week -3, week 87</time_frame>
    <description>Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Android Fat Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Android fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Android Fat Mass (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Android fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gynoid Fat Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Gynoid fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gynoid Fat Mass (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Gynoid fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Appendicular Skeletal Muscle Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Appendicular Skeletal Muscle Mass (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Content (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Bone mineral content was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Density (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Bone mineral density was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-I SDS (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in insulin-like growth factor (IGF-I) standard deviation scores (SDS) was measured from baseline (week -3) until the end of the main treatment period (week 34). A higher score reflects a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-I SDS (Week 87)</measure>
    <time_frame>Week -3, week 87</time_frame>
    <description>Change in IGF-I SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87). A higher score reflects a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGFBP 3 SDS (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in insulin like growth factor binding protein 3 (IGFBP 3) SDS was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGFBP 3 SDS (Week 87)</measure>
    <time_frame>Week -3, week 87</time_frame>
    <description>Change in IGFBP 3 SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRIM-AGHD (Total and Domain Scores) (Week 34)</measure>
    <time_frame>Week 0, week 34</time_frame>
    <description>Change in treatment-related impact measure - adult growth hormone deficiency (TRIM-AGHD) scores (total and domain scores) was measured from baseline (week 0) until the end of the main treatment period (week 34). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRIM-AGHD (Total and Domain Scores) (Week 87)</measure>
    <time_frame>week 0, week 87</time_frame>
    <description>Change in TRIM-AGHD (total and domain scores) was measured from baseline (week 0) until the end of the extension treatment period (week 87). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36v2 (Summary and Domain Scores) (Week 34)</measure>
    <time_frame>Week 0, week 34</time_frame>
    <description>SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36v2 (Summary and Domain Scores) (Week 87)</measure>
    <time_frame>week 0, week 87</time_frame>
    <description>SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSQM-9 Scores (Domain Scores) (Week 34)</measure>
    <time_frame>Week 34</time_frame>
    <description>Scores from the TSQM-9 scale were calculated at the end of the main treatment period (week 34). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSQM-9 Scores (Domain Scores) (Week 87)</measure>
    <time_frame>Week 87</time_frame>
    <description>Scores from the TSQM-9 scale were calculated at the end of the extension treatment period (week 87). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Total cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Total cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-cholesterol (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in High-density lipoprotein (HDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-cholesterol (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in HDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-cholesterol (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Low-density lipoprotein (LDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-cholesterol (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in LDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Triglycerides was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Triglycerides was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hs-CRP (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in high-sensitivity C-reactive protein (hs-CRP) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hs-CRP (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in hs-CRP was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Interleukin 6 (IL-6) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in IL-6 was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in body weight was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in body weight was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in waist circumference was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in waist circumference was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (Weeks 0-35)</measure>
    <time_frame>Weeks 0-35</time_frame>
    <description>Number of adverse events from baseline (week 0) until the end of week 35 were reported. This endpoint shows number of treatment-emergent adverse events (TEAEs), including the injection site reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (Weeks 0-88)</measure>
    <time_frame>Weeks 0-88</time_frame>
    <description>Number of adverse events from baseline (week 0) until the end of week 88 were reported. This endpoint shows the number of TEAEs along with the injection site reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-35)</measure>
    <time_frame>Weeks 0 to 35</time_frame>
    <description>Number of participants with anti-NNC0195-0092 antibodies at week 35 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-88)</measure>
    <time_frame>Weeks 0 to 88</time_frame>
    <description>Number of participants with anti-NNC0195-0092 antibodies at week 88 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-35)</measure>
    <time_frame>Weeks 0 to 35</time_frame>
    <description>Incidence of technical complaints were recorded from baseline (week 0) until week 35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-88)</measure>
    <time_frame>Weeks 0 to 88</time_frame>
    <description>Incidence of technical complaints were recorded from baseline (week 0) until week 88.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Examination During Exposure to Trial Product (Week 35)</measure>
    <time_frame>Week 0 and week 35</time_frame>
    <description>Change in physical examination from baseline (week 0) until the end of the main treatment period (week 35) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central &amp; Peripheral nervous sys. 7) Skin 8) Lymph node palpation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Examination During Exposure to Trial Product (Week 88)</measure>
    <time_frame>Week 0 and week 88</time_frame>
    <description>Change in physical examination from baseline (week 0) until the end of the extension period (week 88) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central &amp; Peripheral nervous sys. 7) Skin 8) Lymph node palpation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Electrocardiogram (ECG) Evaluation During Exposure to Trial Product (Week 35)</measure>
    <time_frame>Week -3 and week 35</time_frame>
    <description>Change in Electrocardiogram (ECG) evaluation from baseline (week -3) until the end of the main treatment period (week 35) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG Evaluation During Exposure to Trial Product (Week 88)</measure>
    <time_frame>Week -3 and week 88</time_frame>
    <description>Change in ECG evaluation from baseline (week 0) until the end of the extension period (Week 88) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure (Week 35)</measure>
    <time_frame>Week -3, week 35</time_frame>
    <description>Change in diastolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure (Week 88)</measure>
    <time_frame>Week -3, week 88</time_frame>
    <description>Change in diastolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period week 88.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (Week 35)</measure>
    <time_frame>Week -3, week 35</time_frame>
    <description>Change in systolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (Week 88)</measure>
    <time_frame>Week -3, week 88</time_frame>
    <description>Change in systolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period (week 88).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse (Week 35)</measure>
    <time_frame>Week -3, week 35</time_frame>
    <description>Change in pulse was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse (Week 88)</measure>
    <time_frame>Week -3, week 88</time_frame>
    <description>Change in pulse was measured from baseline (week -3) until the end of the extension treatment period (week 88).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haemoglobin (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Haemoglobin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haemoglobin (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Haemoglobin was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haematocrit (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Haematocrit was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haematocrit (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Haematocrit was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythrocytes (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Erythrocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythrocytes (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Erythrocytes was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Corpuscular Volume (MCV) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Corpuscular Volume (MCV) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombocytes (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Thrombocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombocytes (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Thrombocytes was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leucocytes (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Leucocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leucocytes (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Leucocytes was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in ALT was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in ALT was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Albumin (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Albumin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Albumin (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Albumin was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alkaline Phosphatase (ALP) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Alkaline phosphatase (ALP) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alkaline Phosphatase (AP) (Week 87)</measure>
    <time_frame>Week -3, week 87</time_frame>
    <description>Change in Alkaline phosphatase (AP) was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in AST was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST) (Week 87)</measure>
    <time_frame>Week -3, week 87</time_frame>
    <description>Change in AST was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bilirubin (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Bilirubin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bilirubin (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Bilirubin was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Calcium (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Calcium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Calcium (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Calcium was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Chloride (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Chloride was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Chloride (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Chloride was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatinine (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Creatinine was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatinine (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Creatinine was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatine Kinase (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Creatine kinase was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatine Kinase (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Creatine kinase was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gamma-glutamyl Transferase (GGT) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in GGT was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gamma-glutamyl Transferase (GGT) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in GGT was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Phosphate (Inorganic) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Phosphate (Inorganic)(Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Potassium (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Potassium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Potassium (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Potassium was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sodium (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Sodium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sodium (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Sodium was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Protein (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in total protein was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Protein (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in total protein was measured from baseline (week -3) until the end of extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urea (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Urea was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urea (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Urea was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Uric acid was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Uric acid was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (GFR) Creatinine (CKD-EPI) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated GFR Creatinine (CKD-EPI) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Fasting plasma glucosewas measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Fasting plasma glucose was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Fasting insulin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Fasting insulin was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Steady State Beta Cell Function (%B) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Steady State Beta Cell Function (%B) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the week 87.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance (IR %) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance (IR %) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycated Haemoglobin (HbA1c) (%) (Week 34)</measure>
    <time_frame>Week -3, week 34</time_frame>
    <description>Change in Glycated haemoglobin (HbA1c) (%) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycated Haemoglobin (HbA1c) (%) (Week 87)</measure>
    <time_frame>week -3, week 87</time_frame>
    <description>Change in Glycated haemoglobin (HbA1c) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>NNC0195-0092 (somapacitan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily hGH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Switch to NNC0195-0092 (somapacitan) treatment in the extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somapacitan</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.</description>
    <arm_group_label>NNC0195-0092 (somapacitan)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NNC0195-0092</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.</description>
    <arm_group_label>Daily hGH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of at least 23 years of age and not more than 79 years of age at the&#xD;
             time of signing informed consent&#xD;
&#xD;
          -  Human growth hormone (hGH) treatment naïve or no exposure to hGH or growth hormone&#xD;
             (GH) secretagogues for at least 180 days prior to randomisation with any registered or&#xD;
             investigational hGH or GH secretagogue product (if only used in connection with&#xD;
             stimulation tests for diagnosis of growth hormone deficiency (GHD), subjects can be&#xD;
             included)&#xD;
&#xD;
          -  If applicable, hormone replacement therapies for any other hormone deficiencies,&#xD;
             adequate and stable for at least 90 days prior to randomisation as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  FOR ALL COUNTRIES EXCEPT JAPAN:&#xD;
&#xD;
        Confirmed diagnosis of adult growth hormone deficiency (Subjects must satisfy one of the&#xD;
        following criterion and documentation of test results must be available before&#xD;
        randomisation (either from subjects' file or new test):&#xD;
&#xD;
          1. Insulin tolerance test (ITT) or glucagon test: a peak GH response of less than 3 ng/mL&#xD;
             (3 mcg/L)&#xD;
&#xD;
          2. Growth hormone releasing hormone (GHRH) + arginine test according to body mass index&#xD;
             (BMI): i) BMI less than 25 kg/m^2, a peak GH less than 11 ng/mL (11 mcg/L), ii) BMI&#xD;
             25-30 kg/m^2, a peak GH less than 8 ng/mL (8 mcg/L), iii) BMI greater than 30 kg/m^2,&#xD;
             a peak GH less than 4 ng/mL (4 mcg/L)&#xD;
&#xD;
          3. Three or more pituitary hormone deficiencies and insulin like growth factor - I&#xD;
             standard deviation score (IGF-I SDS) less than -2.0 - FOR JAPAN ONLY: Confirmed&#xD;
             diagnosis of adult growth hormone deficiency (subjects with adult onset adult growth&#xD;
             hormone deficiency (AGHD) need to satisfy at least one of the following criteria,&#xD;
             subjects with a history of childhood GHD need to satisfy at least 2 of the following&#xD;
             criteria):&#xD;
&#xD;
        a. ITT test: a peak GH of less than or equal to 1.8 ng/mL (assay using recombinant GH&#xD;
        standard) b. glucagon test: a peak GH of less than or equal to 1.8 ng/mL (assay using&#xD;
        recombinant GH standard) c. growth hormone releasing peptide 2 (GHRP-2) tolerance test: a&#xD;
        peak GH of less than or equal to 9 ng/mL (assay using recombinant GH standard)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignant disease or history of malignancy. Exceptions to this exclusion&#xD;
             criterion: - Resection in situ carcinoma of the cervix uteri. Complete eradication of&#xD;
             squamous cell or basal cell carcinoma of the skin&#xD;
&#xD;
          -  Subjects with GHD attributed to treatment of intracranial malignant tumours or&#xD;
             leukaemia, provided that a recurrence-free survival period of at least 5 years is&#xD;
             documented in the subject's file&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure' (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-4120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-5789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01228-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13352</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Dehli</city>
        <state>New Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telengana</state>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700032</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chiba-shi, Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamamatsu-shi, Shizuoka</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyoto-shi Kyoto</city>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sagamihara-shi, Kanagawa</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sappro-shi, Hokkaido</city>
        <zip>060 8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>134-0088</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yamagata-shi, Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-311</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj</state>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures</state>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0044</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tygerberg</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>01021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Johannsson G, Gordon MB, Hojby Rasmussen M, Hakonsson IH, Karges W, Svaerke C, Tahara S, Takano K, Biller BMK. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1358-76. doi: 10.1210/clinem/dgaa049.</citation>
    <PMID>32022863</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <results_first_submitted>April 3, 2020</results_first_submitted>
  <results_first_submitted_qc>June 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <disposition_first_submitted>April 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 9, 2018</disposition_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02229851/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02229851/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 92 sites in 16 countries: Australia - 8, Germany - 4, India - 5, Japan - 14, Latvia - 1, Lithuania - 2, Malaysia - 3, Poland - 5, Romania - 5, Russian Fed. - 6, South Africa - 3, Sweden - 1, Turkey - 4, Ukraine - 1, United Kingdom - 4, United States - 26.</recruitment_details>
      <pre_assignment_details>The trial had a main phase and an extension phase. Participants were treated for 34 weeks in the main phase (followed by 1 week washout) and for 52 weeks in the extension phase (followed by 1 week washout).300 participants received treatment;1 participant was randomised but didn't receive any treatment and was therefore not included in any analyses</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="P2">
          <title>Norditropin</title>
          <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="P3">
          <title>Somapacitan</title>
          <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="P4">
          <title>Placebo/Somapacitan</title>
          <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
        </group>
        <group group_id="P5">
          <title>Somapacitan/Somapacitan</title>
          <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
        </group>
        <group group_id="P6">
          <title>Norditropin/Norditropin</title>
          <description>Participants who received Norditropin in the main phase were randomised 1:1 to continue with norditropin or switch to somapacitan. Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
        </group>
        <group group_id="P7">
          <title>Norditropin/Somapacitan</title>
          <description>Participants who received Norditropin in the main phase were randomised 1:1 to continue with Norditropin or switch to somapacitan. Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Phase (Double-blind Phase)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="0">This arm is not applicable for the Main phase.</participants>
                <participants group_id="P5" count="0">This arm is not applicable for the Main phase.</participants>
                <participants group_id="P6" count="0">This arm is not applicable for the Main phase.</participants>
                <participants group_id="P7" count="0">This arm is not applicable for the Main phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="114"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase (Open-label Phase)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This arm is not applicable for the Extension phase.</participants>
                <participants group_id="P2" count="0">This arm is not applicable for the Extension phase.</participants>
                <participants group_id="P3" count="0">This arm is not applicable for the Extension phase.</participants>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="114"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="109"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="B2">
          <title>Norditropin</title>
          <description>Participants received Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.&#xD;
Participants were re-randomised to receive somapacitan while other continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension part of the trial.</description>
        </group>
        <group group_id="B3">
          <title>Somapacitan</title>
          <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial. Participants continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="15.7"/>
                    <measurement group_id="B2" value="45.7" spread="15.3"/>
                    <measurement group_id="B3" value="44.6" spread="14.3"/>
                    <measurement group_id="B4" value="45.1" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Truncal Fat Percentage (Week 34)</title>
        <description>Change in Truncal fat percentage was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Truncal Fat Percentage (Week 34)</title>
          <description>Change in Truncal fat percentage was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of truncal fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="3.31"/>
                    <measurement group_id="O2" value="-2.39" spread="4.48"/>
                    <measurement group_id="O3" value="-1.17" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Changes in truncal fat percentage from baseline to the 34 week's measurements was analysed using an analysis of covariance model with treatment, growth hormone deficiency (GHD) onset type, sex, region, diabetes mellitus (DM) and sex by region by DM interaction as factors and baseline as a covariate. The analysis was conducted using a multiple imputation technique where trajectory after a withdrawn subjects last observation was imputed based on data from the placebo arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0090</p_value>
            <method>ANCOVA</method>
            <param_type>Treatment difference</param_type>
            <param_value>-1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.68</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
            <estimate_desc>Somapacitan-Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Truncal Fat Percentage (Week 87)</title>
        <description>Change in Truncal fat percentage was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Truncal Fat Percentage (Week 87)</title>
          <description>Change in Truncal fat percentage was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of truncal fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="3.94"/>
                    <measurement group_id="O2" value="-1.63" spread="3.65"/>
                    <measurement group_id="O3" value="-2.63" spread="4.65"/>
                    <measurement group_id="O4" value="-0.96" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Truncal Fat Mass (Week 34)</title>
        <description>Change in Truncal fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Truncal Fat Mass (Week 34)</title>
          <description>Change in Truncal fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.86" spread="1536.36"/>
                    <measurement group_id="O2" value="-619.67" spread="1887.50"/>
                    <measurement group_id="O3" value="-180.98" spread="1762.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Truncal Fat Mass (Week 87)</title>
        <description>Change in Truncal fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Truncal Fat Mass (Week 87)</title>
          <description>Change in Truncal fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-311.85" spread="1771.78"/>
                    <measurement group_id="O2" value="-196.18" spread="2249.21"/>
                    <measurement group_id="O3" value="-685.56" spread="2258.93"/>
                    <measurement group_id="O4" value="364.08" spread="2548.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Truncal Lean Body Mass (Week 34)</title>
        <description>Change in Truncal lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Truncal Lean Body Mass (Week 34)</title>
          <description>Change in Truncal lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.69" spread="1247.67"/>
                    <measurement group_id="O2" value="832.77" spread="1409.74"/>
                    <measurement group_id="O3" value="800.27" spread="1377.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Truncal Lean Body Mass (Week 87)</title>
        <description>Change in Truncal lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Truncal Lean Body Mass (Week 87)</title>
          <description>Change in Truncal lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1197.30" spread="1500.56"/>
                    <measurement group_id="O2" value="1152.79" spread="1480.06"/>
                    <measurement group_id="O3" value="975.79" spread="1258.62"/>
                    <measurement group_id="O4" value="1015.12" spread="1554.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Fat Mass (Week 34)</title>
        <description>Change in Total fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Fat Mass (Week 34)</title>
          <description>Change in Total fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.47" spread="2689.06"/>
                    <measurement group_id="O2" value="-855.71" spread="3167.06"/>
                    <measurement group_id="O3" value="-85.47" spread="3022.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Fat Mass (Week 87)</title>
        <description>Change in total fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>Week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Fat Mass (Week 87)</title>
          <description>Change in total fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-540.04" spread="3250.16"/>
                    <measurement group_id="O2" value="-118.07" spread="3795.36"/>
                    <measurement group_id="O3" value="-923.01" spread="4099.45"/>
                    <measurement group_id="O4" value="874.56" spread="4789.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visceral Adipose Tissue (Week 34)</title>
        <description>Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Adipose Tissue (Week 34)</title>
          <description>Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>centimeter square</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="13.81"/>
                    <measurement group_id="O2" value="-9.68" spread="21.37"/>
                    <measurement group_id="O3" value="-11.61" spread="23.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visceral Adipose Tissue (Week 87)</title>
        <description>Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>Week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Adipose Tissue (Week 87)</title>
          <description>Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>centimeter square</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.34" spread="25.67"/>
                    <measurement group_id="O2" value="-6.71" spread="33.07"/>
                    <measurement group_id="O3" value="-5.17" spread="20.11"/>
                    <measurement group_id="O4" value="-5.97" spread="28.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Android Fat Mass (Week 34)</title>
        <description>Change in Android fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Android Fat Mass (Week 34)</title>
          <description>Change in Android fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.32" spread="293.93"/>
                    <measurement group_id="O2" value="-158.98" spread="325.35"/>
                    <measurement group_id="O3" value="-81.52" spread="361.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Android Fat Mass (Week 87)</title>
        <description>Change in Android fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Android Fat Mass (Week 87)</title>
          <description>Change in Android fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-107.16" spread="367.14"/>
                    <measurement group_id="O2" value="-39.76" spread="481.66"/>
                    <measurement group_id="O3" value="-100.76" spread="386.24"/>
                    <measurement group_id="O4" value="11.52" spread="489.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gynoid Fat Mass (Week 34)</title>
        <description>Change in Gynoid fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gynoid Fat Mass (Week 34)</title>
          <description>Change in Gynoid fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="567.04"/>
                    <measurement group_id="O2" value="-128.59" spread="471.00"/>
                    <measurement group_id="O3" value="22.66" spread="510.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gynoid Fat Mass (Week 87)</title>
        <description>Change in Gynoid fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gynoid Fat Mass (Week 87)</title>
          <description>Change in Gynoid fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.00" spread="759.37"/>
                    <measurement group_id="O2" value="10.23" spread="557.20"/>
                    <measurement group_id="O3" value="-100.97" spread="620.16"/>
                    <measurement group_id="O4" value="140.02" spread="790.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Appendicular Skeletal Muscle Mass (Week 34)</title>
        <description>Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Appendicular Skeletal Muscle Mass (Week 34)</title>
          <description>Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.22" spread="1006.58"/>
                    <measurement group_id="O2" value="482.76" spread="1246.89"/>
                    <measurement group_id="O3" value="565.21" spread="1011.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Appendicular Skeletal Muscle Mass (Week 87)</title>
        <description>Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Appendicular Skeletal Muscle Mass (Week 87)</title>
          <description>Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.96" spread="1688.08"/>
                    <measurement group_id="O2" value="538.45" spread="1224.13"/>
                    <measurement group_id="O3" value="464.75" spread="1513.96"/>
                    <measurement group_id="O4" value="632.18" spread="1928.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass (Week 34)</title>
        <description>Change in Lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass (Week 34)</title>
          <description>Change in Lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.43" spread="2048.01"/>
                    <measurement group_id="O2" value="1359.33" spread="2359.11"/>
                    <measurement group_id="O3" value="1395.88" spread="2139.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass (Week 87)</title>
        <description>Change in Lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass (Week 87)</title>
          <description>Change in Lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1717.15" spread="2965.23"/>
                    <measurement group_id="O2" value="1719.87" spread="2515.90"/>
                    <measurement group_id="O3" value="1464.51" spread="2439.75"/>
                    <measurement group_id="O4" value="1681.82" spread="3413.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Mineral Content (Week 87)</title>
        <description>Change in Bone mineral content was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Content (Week 87)</title>
          <description>Change in Bone mineral content was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.61" spread="93.35"/>
                    <measurement group_id="O2" value="5.02" spread="113.81"/>
                    <measurement group_id="O3" value="-10.18" spread="99.18"/>
                    <measurement group_id="O4" value="32.33" spread="87.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Mineral Density (Week 87)</title>
        <description>Change in Bone mineral density was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density (Week 87)</title>
          <description>Change in Bone mineral density was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>grams per square centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.04"/>
                    <measurement group_id="O2" value="-0.00" spread="0.04"/>
                    <measurement group_id="O3" value="-0.00" spread="0.04"/>
                    <measurement group_id="O4" value="0.01" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IGF-I SDS (Week 34)</title>
        <description>Change in insulin-like growth factor (IGF-I) standard deviation scores (SDS) was measured from baseline (week -3) until the end of the main treatment period (week 34). A higher score reflects a better outcome.</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IGF-I SDS (Week 34)</title>
          <description>Change in insulin-like growth factor (IGF-I) standard deviation scores (SDS) was measured from baseline (week -3) until the end of the main treatment period (week 34). A higher score reflects a better outcome.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Standard deviation score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.59"/>
                    <measurement group_id="O2" value="2.28" spread="1.32"/>
                    <measurement group_id="O3" value="2.37" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IGF-I SDS (Week 87)</title>
        <description>Change in IGF-I SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87). A higher score reflects a better outcome.</description>
        <time_frame>Week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IGF-I SDS (Week 87)</title>
          <description>Change in IGF-I SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87). A higher score reflects a better outcome.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Standard deviation score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="1.55"/>
                    <measurement group_id="O2" value="2.29" spread="1.39"/>
                    <measurement group_id="O3" value="2.07" spread="1.12"/>
                    <measurement group_id="O4" value="2.35" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IGFBP 3 SDS (Week 34)</title>
        <description>Change in insulin like growth factor binding protein 3 (IGFBP 3) SDS was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IGFBP 3 SDS (Week 34)</title>
          <description>Change in insulin like growth factor binding protein 3 (IGFBP 3) SDS was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Standard deviation score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.61"/>
                    <measurement group_id="O2" value="1.44" spread="1.17"/>
                    <measurement group_id="O3" value="1.56" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IGFBP 3 SDS (Week 87)</title>
        <description>Change in IGFBP 3 SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>Week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IGFBP 3 SDS (Week 87)</title>
          <description>Change in IGFBP 3 SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Standard deviation score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.20"/>
                    <measurement group_id="O2" value="1.41" spread="1.20"/>
                    <measurement group_id="O3" value="1.30" spread="1.08"/>
                    <measurement group_id="O4" value="1.47" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TRIM-AGHD (Total and Domain Scores) (Week 34)</title>
        <description>Change in treatment-related impact measure - adult growth hormone deficiency (TRIM-AGHD) scores (total and domain scores) was measured from baseline (week 0) until the end of the main treatment period (week 34). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.</description>
        <time_frame>Week 0, week 34</time_frame>
        <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TRIM-AGHD (Total and Domain Scores) (Week 34)</title>
          <description>Change in treatment-related impact measure - adult growth hormone deficiency (TRIM-AGHD) scores (total and domain scores) was measured from baseline (week 0) until the end of the main treatment period (week 34). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.</description>
          <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Energy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.96" spread="25.40"/>
                    <measurement group_id="O2" value="-13.42" spread="23.73"/>
                    <measurement group_id="O3" value="-7.81" spread="24.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.38" spread="12.15"/>
                    <measurement group_id="O2" value="-8.93" spread="14.21"/>
                    <measurement group_id="O3" value="-4.63" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="18.17"/>
                    <measurement group_id="O2" value="-7.06" spread="18.47"/>
                    <measurement group_id="O3" value="-3.92" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.88" spread="14.72"/>
                    <measurement group_id="O2" value="-11.33" spread="19.23"/>
                    <measurement group_id="O3" value="-7.39" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.65" spread="12.05"/>
                    <measurement group_id="O2" value="-9.99" spread="13.64"/>
                    <measurement group_id="O3" value="-5.71" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TRIM-AGHD (Total and Domain Scores) (Week 87)</title>
        <description>Change in TRIM-AGHD (total and domain scores) was measured from baseline (week 0) until the end of the extension treatment period (week 87). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.</description>
        <time_frame>week 0, week 87</time_frame>
        <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TRIM-AGHD (Total and Domain Scores) (Week 87)</title>
          <description>Change in TRIM-AGHD (total and domain scores) was measured from baseline (week 0) until the end of the extension treatment period (week 87). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.</description>
          <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Energy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.73" spread="30.87"/>
                    <measurement group_id="O2" value="-8.11" spread="25.46"/>
                    <measurement group_id="O3" value="-23.30" spread="28.03"/>
                    <measurement group_id="O4" value="-9.13" spread="26.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.97" spread="16.05"/>
                    <measurement group_id="O2" value="-6.64" spread="14.56"/>
                    <measurement group_id="O3" value="-15.64" spread="15.36"/>
                    <measurement group_id="O4" value="-7.35" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.88" spread="21.19"/>
                    <measurement group_id="O2" value="-5.55" spread="18.59"/>
                    <measurement group_id="O3" value="-14.18" spread="20.29"/>
                    <measurement group_id="O4" value="-7.71" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.19" spread="20.13"/>
                    <measurement group_id="O2" value="-9.57" spread="21.94"/>
                    <measurement group_id="O3" value="-17.22" spread="27.02"/>
                    <measurement group_id="O4" value="-13.54" spread="18.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.28" spread="15.88"/>
                    <measurement group_id="O2" value="-7.25" spread="14.42"/>
                    <measurement group_id="O3" value="-17.38" spread="16.77"/>
                    <measurement group_id="O4" value="-8.67" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36v2 (Summary and Domain Scores) (Week 34)</title>
        <description>SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.</description>
        <time_frame>Week 0, week 34</time_frame>
        <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36v2 (Summary and Domain Scores) (Week 34)</title>
          <description>SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.</description>
          <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="6.44"/>
                    <measurement group_id="O2" value="2.46" spread="7.08"/>
                    <measurement group_id="O3" value="3.18" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="7.68"/>
                    <measurement group_id="O2" value="3.95" spread="8.48"/>
                    <measurement group_id="O3" value="3.14" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="9.52"/>
                    <measurement group_id="O2" value="3.50" spread="10.87"/>
                    <measurement group_id="O3" value="3.06" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="7.67"/>
                    <measurement group_id="O2" value="5.26" spread="9.89"/>
                    <measurement group_id="O3" value="2.38" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to mental health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="9.59"/>
                    <measurement group_id="O2" value="3.72" spread="10.17"/>
                    <measurement group_id="O3" value="2.78" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="10.43"/>
                    <measurement group_id="O2" value="3.19" spread="9.80"/>
                    <measurement group_id="O3" value="2.87" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="8.79"/>
                    <measurement group_id="O2" value="2.19" spread="9.50"/>
                    <measurement group_id="O3" value="1.79" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="7.25"/>
                    <measurement group_id="O2" value="4.47" spread="7.64"/>
                    <measurement group_id="O3" value="1.85" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall physical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="6.22"/>
                    <measurement group_id="O2" value="2.87" spread="6.33"/>
                    <measurement group_id="O3" value="2.40" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall mental</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="8.72"/>
                    <measurement group_id="O2" value="4.09" spread="10.19"/>
                    <measurement group_id="O3" value="2.70" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36v2 (Summary and Domain Scores) (Week 87)</title>
        <description>SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.</description>
        <time_frame>week 0, week 87</time_frame>
        <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36v2 (Summary and Domain Scores) (Week 87)</title>
          <description>SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.</description>
          <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="8.13"/>
                    <measurement group_id="O2" value="3.83" spread="7.66"/>
                    <measurement group_id="O3" value="3.43" spread="6.96"/>
                    <measurement group_id="O4" value="1.84" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="9.81"/>
                    <measurement group_id="O2" value="4.16" spread="10.10"/>
                    <measurement group_id="O3" value="4.65" spread="10.06"/>
                    <measurement group_id="O4" value="2.45" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="11.59"/>
                    <measurement group_id="O2" value="3.46" spread="12.25"/>
                    <measurement group_id="O3" value="7.30" spread="13.46"/>
                    <measurement group_id="O4" value="1.13" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.71" spread="11.01"/>
                    <measurement group_id="O2" value="4.18" spread="9.30"/>
                    <measurement group_id="O3" value="8.16" spread="12.77"/>
                    <measurement group_id="O4" value="4.16" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to mental health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="10.55"/>
                    <measurement group_id="O2" value="3.66" spread="8.12"/>
                    <measurement group_id="O3" value="6.12" spread="13.02"/>
                    <measurement group_id="O4" value="1.70" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="10.36"/>
                    <measurement group_id="O2" value="3.44" spread="10.29"/>
                    <measurement group_id="O3" value="4.56" spread="10.34"/>
                    <measurement group_id="O4" value="0.57" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="8.57"/>
                    <measurement group_id="O2" value="1.47" spread="10.29"/>
                    <measurement group_id="O3" value="3.51" spread="9.57"/>
                    <measurement group_id="O4" value="0.30" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="7.33"/>
                    <measurement group_id="O2" value="3.32" spread="7.70"/>
                    <measurement group_id="O3" value="5.66" spread="9.67"/>
                    <measurement group_id="O4" value="2.20" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall physical score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="6.91"/>
                    <measurement group_id="O2" value="2.98" spread="7.24"/>
                    <measurement group_id="O3" value="3.06" spread="7.07"/>
                    <measurement group_id="O4" value="1.81" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall mental score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="10.39"/>
                    <measurement group_id="O2" value="3.56" spread="9.06"/>
                    <measurement group_id="O3" value="7.50" spread="13.59"/>
                    <measurement group_id="O4" value="1.66" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TSQM-9 Scores (Domain Scores) (Week 34)</title>
        <description>Scores from the TSQM-9 scale were calculated at the end of the main treatment period (week 34). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.</description>
        <time_frame>Week 34</time_frame>
        <population>Overall number of participants analyzed = FAS. Number analyzed = Number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>TSQM-9 Scores (Domain Scores) (Week 34)</title>
          <description>Scores from the TSQM-9 scale were calculated at the end of the main treatment period (week 34). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.</description>
          <population>Overall number of participants analyzed = FAS. Number analyzed = Number of participants with available data.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effectiveness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" spread="22.2"/>
                    <measurement group_id="O2" value="67.1" spread="21.8"/>
                    <measurement group_id="O3" value="56.1" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenience</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="16.9"/>
                    <measurement group_id="O2" value="73.9" spread="18.7"/>
                    <measurement group_id="O3" value="77.7" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" spread="24.8"/>
                    <measurement group_id="O2" value="69.0" spread="24.0"/>
                    <measurement group_id="O3" value="63.1" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TSQM-9 Scores (Domain Scores) (Week 87)</title>
        <description>Scores from the TSQM-9 scale were calculated at the end of the extension treatment period (week 87). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.</description>
        <time_frame>Week 87</time_frame>
        <population>Overall number of participants analyzed = FAS. Number analyzed = Number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>TSQM-9 Scores (Domain Scores) (Week 87)</title>
          <description>Scores from the TSQM-9 scale were calculated at the end of the extension treatment period (week 87). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.</description>
          <population>Overall number of participants analyzed = FAS. Number analyzed = Number of participants with available data.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effectiveness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" spread="23.1"/>
                    <measurement group_id="O2" value="65.7" spread="22.4"/>
                    <measurement group_id="O3" value="69.6" spread="24.0"/>
                    <measurement group_id="O4" value="70.9" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenience</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="19.1"/>
                    <measurement group_id="O2" value="80.0" spread="16.5"/>
                    <measurement group_id="O3" value="72.6" spread="20.0"/>
                    <measurement group_id="O4" value="79.4" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="26.2"/>
                    <measurement group_id="O2" value="68.1" spread="24.6"/>
                    <measurement group_id="O3" value="71.7" spread="25.3"/>
                    <measurement group_id="O4" value="75.1" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol (Week 34)</title>
        <description>Change in Total cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol (Week 34)</title>
          <description>Change in Total cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.96"/>
                    <measurement group_id="O2" value="-0.10" spread="0.91"/>
                    <measurement group_id="O3" value="-0.09" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol (Week 87)</title>
        <description>Change in Total cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol (Week 87)</title>
          <description>Change in Total cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.89"/>
                    <measurement group_id="O2" value="0.03" spread="0.96"/>
                    <measurement group_id="O3" value="-0.05" spread="0.94"/>
                    <measurement group_id="O4" value="-0.33" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL-cholesterol (Week 34)</title>
        <description>Change in High-density lipoprotein (HDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL-cholesterol (Week 34)</title>
          <description>Change in High-density lipoprotein (HDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.37"/>
                    <measurement group_id="O2" value="0.02" spread="0.28"/>
                    <measurement group_id="O3" value="0.05" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL-cholesterol (Week 87)</title>
        <description>Change in HDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL-cholesterol (Week 87)</title>
          <description>Change in HDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.30"/>
                    <measurement group_id="O2" value="0.05" spread="0.32"/>
                    <measurement group_id="O3" value="0.09" spread="0.27"/>
                    <measurement group_id="O4" value="0.06" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL-cholesterol (Week 34)</title>
        <description>Change in Low-density lipoprotein (LDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL-cholesterol (Week 34)</title>
          <description>Change in Low-density lipoprotein (LDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.75"/>
                    <measurement group_id="O2" value="-0.18" spread="0.72"/>
                    <measurement group_id="O3" value="-0.13" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL-cholesterol (Week 87)</title>
        <description>Change in LDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL-cholesterol (Week 87)</title>
          <description>Change in LDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.72"/>
                    <measurement group_id="O2" value="-0.06" spread="0.81"/>
                    <measurement group_id="O3" value="-0.15" spread="0.85"/>
                    <measurement group_id="O4" value="-0.36" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides (Week 34)</title>
        <description>Change in Triglycerides was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides (Week 34)</title>
          <description>Change in Triglycerides was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.65"/>
                    <measurement group_id="O2" value="0.13" spread="0.62"/>
                    <measurement group_id="O3" value="-0.02" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides (Week 87)</title>
        <description>Change in Triglycerides was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides (Week 87)</title>
          <description>Change in Triglycerides was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.48"/>
                    <measurement group_id="O2" value="0.03" spread="0.76"/>
                    <measurement group_id="O3" value="0.03" spread="0.56"/>
                    <measurement group_id="O4" value="-0.08" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hs-CRP (Week 34)</title>
        <description>Change in high-sensitivity C-reactive protein (hs-CRP) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hs-CRP (Week 34)</title>
          <description>Change in high-sensitivity C-reactive protein (hs-CRP) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.405" spread="13.144"/>
                    <measurement group_id="O2" value="-1.604" spread="13.254"/>
                    <measurement group_id="O3" value="-0.569" spread="5.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hs-CRP (Week 87)</title>
        <description>Change in hs-CRP was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hs-CRP (Week 87)</title>
          <description>Change in hs-CRP was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.325" spread="16.247"/>
                    <measurement group_id="O2" value="-1.445" spread="3.791"/>
                    <measurement group_id="O3" value="-0.857" spread="17.491"/>
                    <measurement group_id="O4" value="-1.257" spread="12.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-6 (Week 34)</title>
        <description>Change in Interleukin 6 (IL-6) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 (Week 34)</title>
          <description>Change in Interleukin 6 (IL-6) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="24.84"/>
                    <measurement group_id="O2" value="0.07" spread="4.01"/>
                    <measurement group_id="O3" value="0.18" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-6 (Week 87)</title>
        <description>Change in IL-6 was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 (Week 87)</title>
          <description>Change in IL-6 was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="3.30"/>
                    <measurement group_id="O2" value="0.52" spread="6.19"/>
                    <measurement group_id="O3" value="0.49" spread="5.12"/>
                    <measurement group_id="O4" value="1.19" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight (Week 34)</title>
        <description>Change in body weight was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight (Week 34)</title>
          <description>Change in body weight was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.9"/>
                    <measurement group_id="O2" value="0.2" spread="4.0"/>
                    <measurement group_id="O3" value="1.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight (Week 87)</title>
        <description>Change in body weight was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight (Week 87)</title>
          <description>Change in body weight was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="4.4"/>
                    <measurement group_id="O2" value="1.4" spread="4.8"/>
                    <measurement group_id="O3" value="0.4" spread="5.2"/>
                    <measurement group_id="O4" value="2.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference (Week 34)</title>
        <description>Change in waist circumference was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference (Week 34)</title>
          <description>Change in waist circumference was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="4.50"/>
                    <measurement group_id="O2" value="-0.66" spread="4.83"/>
                    <measurement group_id="O3" value="-0.00" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference (Week 87)</title>
        <description>Change in waist circumference was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analysed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference (Week 87)</title>
          <description>Change in waist circumference was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analysed = number of participants with available data.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="5.62"/>
                    <measurement group_id="O2" value="0.53" spread="5.17"/>
                    <measurement group_id="O3" value="-2.26" spread="7.93"/>
                    <measurement group_id="O4" value="0.74" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (Weeks 0-35)</title>
        <description>Number of adverse events from baseline (week 0) until the end of week 35 were reported. This endpoint shows number of treatment-emergent adverse events (TEAEs), including the injection site reactions.</description>
        <time_frame>Weeks 0-35</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (Weeks 0-35)</title>
          <description>Number of adverse events from baseline (week 0) until the end of week 35 were reported. This endpoint shows number of treatment-emergent adverse events (TEAEs), including the injection site reactions.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="426"/>
                    <measurement group_id="O3" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (Weeks 0-88)</title>
        <description>Number of adverse events from baseline (week 0) until the end of week 88 were reported. This endpoint shows the number of TEAEs along with the injection site reactions.</description>
        <time_frame>Weeks 0-88</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O5">
            <title>Norditropin/-</title>
            <description>Participants who received Norditropin in the main period of the trial and discontinued after the main period of the study are included here.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (Weeks 0-88)</title>
          <description>Number of adverse events from baseline (week 0) until the end of week 88 were reported. This endpoint shows the number of TEAEs along with the injection site reactions.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="699"/>
                    <measurement group_id="O3" value="384"/>
                    <measurement group_id="O4" value="385"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-35)</title>
        <description>Number of participants with anti-NNC0195-0092 antibodies at week 35 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.</description>
        <time_frame>Weeks 0 to 35</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-35)</title>
          <description>Number of participants with anti-NNC0195-0092 antibodies at week 35 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-88)</title>
        <description>Number of participants with anti-NNC0195-0092 antibodies at week 88 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.</description>
        <time_frame>Weeks 0 to 88</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O5">
            <title>Norditropin/-</title>
            <description>Participants who received Norditropin in the main period of the trial and discontinued after the main period of the study are included here.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-88)</title>
          <description>Number of participants with anti-NNC0195-0092 antibodies at week 88 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-35)</title>
        <description>Incidence of technical complaints were recorded from baseline (week 0) until week 35.</description>
        <time_frame>Weeks 0 to 35</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-35)</title>
          <description>Incidence of technical complaints were recorded from baseline (week 0) until week 35.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Technical complaints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-88)</title>
        <description>Incidence of technical complaints were recorded from baseline (week 0) until week 88.</description>
        <time_frame>Weeks 0 to 88</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-88)</title>
          <description>Incidence of technical complaints were recorded from baseline (week 0) until week 88.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Technical complaints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Examination During Exposure to Trial Product (Week 35)</title>
        <description>Change in physical examination from baseline (week 0) until the end of the main treatment period (week 35) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central &amp; Peripheral nervous sys. 7) Skin 8) Lymph node palpation</description>
        <time_frame>Week 0 and week 35</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Examination During Exposure to Trial Product (Week 35)</title>
          <description>Change in physical examination from baseline (week 0) until the end of the main treatment period (week 35) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central &amp; Peripheral nervous sys. 7) Skin 8) Lymph node palpation</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Head, neck, eyes, nose (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head, neck, eyes, nose (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory sys. (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular sys. (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal sys. (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal sys. (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central &amp; Peripheral nervous sys (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central &amp; Peripheral nervous sys (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node palpation (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node palpation (Week 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, not clinically significant (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, clinically significant (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Examination During Exposure to Trial Product (Week 88)</title>
        <description>Change in physical examination from baseline (week 0) until the end of the extension period (week 88) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central &amp; Peripheral nervous sys. 7) Skin 8) Lymph node palpation</description>
        <time_frame>Week 0 and week 88</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O5">
            <title>Norditropin/-</title>
            <description>Participants who received Norditropin in the main period of the trial and discontinued after the main period of the study are included here.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Examination During Exposure to Trial Product (Week 88)</title>
          <description>Change in physical examination from baseline (week 0) until the end of the extension period (week 88) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central &amp; Peripheral nervous sys. 7) Skin 8) Lymph node palpation</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Head, neck, eyes, nose (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head, neck, eyes, nose (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory sys. (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular sys. (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal sys. (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal sys. (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal sys. (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central &amp; Peripheral nervous sys. (week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central &amp; Peripheral nervous sys. (week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node palpation (week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node palpation (week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Electrocardiogram (ECG) Evaluation During Exposure to Trial Product (Week 35)</title>
        <description>Change in Electrocardiogram (ECG) evaluation from baseline (week -3) until the end of the main treatment period (week 35) was reported.</description>
        <time_frame>Week -3 and week 35</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Electrocardiogram (ECG) Evaluation During Exposure to Trial Product (Week 35)</title>
          <description>Change in Electrocardiogram (ECG) evaluation from baseline (week -3) until the end of the main treatment period (week 35) was reported.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG Evaluation During Exposure to Trial Product (Week 88)</title>
        <description>Change in ECG evaluation from baseline (week 0) until the end of the extension period (Week 88) was reported.</description>
        <time_frame>Week -3 and week 88</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O5">
            <title>Norditropin/-</title>
            <description>Participants who received Norditropin in the main period of the trial and discontinued after the main period of the study are included here.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG Evaluation During Exposure to Trial Product (Week 88)</title>
          <description>Change in ECG evaluation from baseline (week 0) until the end of the extension period (Week 88) was reported.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure (Week 35)</title>
        <description>Change in diastolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
        <time_frame>Week -3, week 35</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (Week 35)</title>
          <description>Change in diastolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="7.75"/>
                    <measurement group_id="O2" value="-2.07" spread="8.73"/>
                    <measurement group_id="O3" value="-1.42" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure (Week 88)</title>
        <description>Change in diastolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period week 88.</description>
        <time_frame>Week -3, week 88</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (Week 88)</title>
          <description>Change in diastolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period week 88.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="7.77"/>
                    <measurement group_id="O2" value="-0.85" spread="9.21"/>
                    <measurement group_id="O3" value="-0.61" spread="8.71"/>
                    <measurement group_id="O4" value="-2.10" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (Week 35)</title>
        <description>Change in systolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
        <time_frame>Week -3, week 35</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (Week 35)</title>
          <description>Change in systolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="11.35"/>
                    <measurement group_id="O2" value="-2.81" spread="13.33"/>
                    <measurement group_id="O3" value="-1.39" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (Week 88)</title>
        <description>Change in systolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period (week 88).</description>
        <time_frame>Week -3, week 88</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (Week 88)</title>
          <description>Change in systolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period (week 88).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="12.18"/>
                    <measurement group_id="O2" value="0.45" spread="13.01"/>
                    <measurement group_id="O3" value="-1.35" spread="13.07"/>
                    <measurement group_id="O4" value="-1.83" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulse (Week 35)</title>
        <description>Change in pulse was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
        <time_frame>Week -3, week 35</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse (Week 35)</title>
          <description>Change in pulse was measured from baseline (week -3) until the end of the main treatment period (week 35).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="9.43"/>
                    <measurement group_id="O2" value="2.61" spread="9.74"/>
                    <measurement group_id="O3" value="1.02" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulse (Week 88)</title>
        <description>Change in pulse was measured from baseline (week -3) until the end of the extension treatment period (week 88).</description>
        <time_frame>Week -3, week 88</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse (Week 88)</title>
          <description>Change in pulse was measured from baseline (week -3) until the end of the extension treatment period (week 88).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="11.70"/>
                    <measurement group_id="O2" value="-0.55" spread="10.51"/>
                    <measurement group_id="O3" value="-0.55" spread="10.32"/>
                    <measurement group_id="O4" value="0.08" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haemoglobin (Week 34)</title>
        <description>Change in Haemoglobin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haemoglobin (Week 34)</title>
          <description>Change in Haemoglobin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="10.25"/>
                    <measurement group_id="O2" value="-0.51" spread="8.80"/>
                    <measurement group_id="O3" value="0.64" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haemoglobin (Week 87)</title>
        <description>Change in Haemoglobin was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haemoglobin (Week 87)</title>
          <description>Change in Haemoglobin was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="11.36"/>
                    <measurement group_id="O2" value="2.76" spread="9.54"/>
                    <measurement group_id="O3" value="-0.40" spread="9.22"/>
                    <measurement group_id="O4" value="0.86" spread="15.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haematocrit (Week 34)</title>
        <description>Change in Haematocrit was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haematocrit (Week 34)</title>
          <description>Change in Haematocrit was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>% of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.3"/>
                    <measurement group_id="O2" value="-0.3" spread="2.9"/>
                    <measurement group_id="O3" value="0.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haematocrit (Week 87)</title>
        <description>Change in Haematocrit was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haematocrit (Week 87)</title>
          <description>Change in Haematocrit was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>% of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="3.44"/>
                    <measurement group_id="O2" value="0.21" spread="3.29"/>
                    <measurement group_id="O3" value="-0.59" spread="2.78"/>
                    <measurement group_id="O4" value="-0.48" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Erythrocytes (Week 34)</title>
        <description>Change in Erythrocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erythrocytes (Week 34)</title>
          <description>Change in Erythrocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>cells/pL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.33"/>
                    <measurement group_id="O2" value="0.06" spread="0.29"/>
                    <measurement group_id="O3" value="0.08" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Erythrocytes (Week 87)</title>
        <description>Change in Erythrocytes was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erythrocytes (Week 87)</title>
          <description>Change in Erythrocytes was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>cells/pL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.34"/>
                    <measurement group_id="O2" value="0.12" spread="0.35"/>
                    <measurement group_id="O3" value="0.01" spread="0.31"/>
                    <measurement group_id="O4" value="0.05" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Corpuscular Volume (MCV) (Week 34)</title>
        <description>Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Volume (MCV) (Week 34)</title>
          <description>Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.3"/>
                    <measurement group_id="O2" value="-1.8" spread="3.6"/>
                    <measurement group_id="O3" value="-1.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Corpuscular Volume (MCV) (Week 87)</title>
        <description>Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Volume (MCV) (Week 87)</title>
          <description>Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="4.27"/>
                    <measurement group_id="O2" value="-1.80" spread="3.31"/>
                    <measurement group_id="O3" value="-1.31" spread="3.63"/>
                    <measurement group_id="O4" value="-1.77" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 34)</title>
        <description>Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 34)</title>
          <description>Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.6"/>
                    <measurement group_id="O3" value="0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 87)</title>
        <description>Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 87)</title>
          <description>Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.47"/>
                    <measurement group_id="O2" value="0.29" spread="0.61"/>
                    <measurement group_id="O3" value="0.23" spread="0.70"/>
                    <measurement group_id="O4" value="0.35" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombocytes (Week 34)</title>
        <description>Change in Thrombocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombocytes (Week 34)</title>
          <description>Change in Thrombocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="37.4"/>
                    <measurement group_id="O2" value="10.8" spread="37.1"/>
                    <measurement group_id="O3" value="15.3" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombocytes (Week 87)</title>
        <description>Change in Thrombocytes was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombocytes (Week 87)</title>
          <description>Change in Thrombocytes was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="44.7"/>
                    <measurement group_id="O2" value="11.0" spread="36.7"/>
                    <measurement group_id="O3" value="-0.9" spread="31.3"/>
                    <measurement group_id="O4" value="6.6" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leucocytes (Week 34)</title>
        <description>Change in Leucocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leucocytes (Week 34)</title>
          <description>Change in Leucocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="1.57"/>
                    <measurement group_id="O2" value="-0.05" spread="1.50"/>
                    <measurement group_id="O3" value="-0.32" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leucocytes (Week 87)</title>
        <description>Change in Leucocytes was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leucocytes (Week 87)</title>
          <description>Change in Leucocytes was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="1.93"/>
                    <measurement group_id="O2" value="-0.12" spread="1.94"/>
                    <measurement group_id="O3" value="-0.14" spread="1.44"/>
                    <measurement group_id="O4" value="-0.14" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) (Week 34)</title>
        <description>Change in ALT was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT) (Week 34)</title>
          <description>Change in ALT was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="24.7"/>
                    <measurement group_id="O2" value="-1.4" spread="11.9"/>
                    <measurement group_id="O3" value="-4.4" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) (Week 87)</title>
        <description>Change in ALT was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT) (Week 87)</title>
          <description>Change in ALT was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="13.1"/>
                    <measurement group_id="O2" value="-4.3" spread="16.9"/>
                    <measurement group_id="O3" value="0.6" spread="12.5"/>
                    <measurement group_id="O4" value="-3.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Albumin (Week 34)</title>
        <description>Change in Albumin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Albumin (Week 34)</title>
          <description>Change in Albumin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="3.56"/>
                    <measurement group_id="O2" value="-0.72" spread="2.81"/>
                    <measurement group_id="O3" value="-0.42" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Albumin (Week 87)</title>
        <description>Change in Albumin was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Albumin (Week 87)</title>
          <description>Change in Albumin was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="3.15"/>
                    <measurement group_id="O2" value="-0.86" spread="3.12"/>
                    <measurement group_id="O3" value="-1.12" spread="3.52"/>
                    <measurement group_id="O4" value="-1.69" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alkaline Phosphatase (ALP) (Week 34)</title>
        <description>Change in Alkaline phosphatase (ALP) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alkaline Phosphatase (ALP) (Week 34)</title>
          <description>Change in Alkaline phosphatase (ALP) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="16.5"/>
                    <measurement group_id="O2" value="7.9" spread="24.3"/>
                    <measurement group_id="O3" value="5.8" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alkaline Phosphatase (AP) (Week 87)</title>
        <description>Change in Alkaline phosphatase (AP) was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>Week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alkaline Phosphatase (AP) (Week 87)</title>
          <description>Change in Alkaline phosphatase (AP) was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="20.2"/>
                    <measurement group_id="O2" value="5.4" spread="16.0"/>
                    <measurement group_id="O3" value="3.3" spread="22.2"/>
                    <measurement group_id="O4" value="4.2" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aspartate Aminotransferase (AST) (Week 34)</title>
        <description>Change in AST was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Aminotransferase (AST) (Week 34)</title>
          <description>Change in AST was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="15.11"/>
                    <measurement group_id="O2" value="-0.80" spread="9.38"/>
                    <measurement group_id="O3" value="-2.00" spread="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aspartate Aminotransferase (AST) (Week 87)</title>
        <description>Change in AST was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>Week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Aminotransferase (AST) (Week 87)</title>
          <description>Change in AST was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="24.346"/>
                    <measurement group_id="O2" value="-2.17" spread="13.98"/>
                    <measurement group_id="O3" value="-0.43" spread="5.94"/>
                    <measurement group_id="O4" value="-1.69" spread="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bilirubin (Week 34)</title>
        <description>Change in Bilirubin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bilirubin (Week 34)</title>
          <description>Change in Bilirubin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="4.76"/>
                    <measurement group_id="O2" value="-0.38" spread="4.10"/>
                    <measurement group_id="O3" value="-0.41" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bilirubin (Week 87)</title>
        <description>Change in Bilirubin was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bilirubin (Week 87)</title>
          <description>Change in Bilirubin was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="3.77"/>
                    <measurement group_id="O2" value="0.14" spread="4.45"/>
                    <measurement group_id="O3" value="0.45" spread="3.24"/>
                    <measurement group_id="O4" value="-0.33" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Calcium (Week 34)</title>
        <description>Change in Calcium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Calcium (Week 34)</title>
          <description>Change in Calcium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.13"/>
                    <measurement group_id="O2" value="0.04" spread="0.14"/>
                    <measurement group_id="O3" value="0.03" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Calcium (Week 87)</title>
        <description>Change in Calcium was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Calcium (Week 87)</title>
          <description>Change in Calcium was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.12"/>
                    <measurement group_id="O2" value="0.03" spread="0.12"/>
                    <measurement group_id="O3" value="0.03" spread="0.11"/>
                    <measurement group_id="O4" value="0.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Chloride (Week 34)</title>
        <description>Change in Chloride was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chloride (Week 34)</title>
          <description>Change in Chloride was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.7"/>
                    <measurement group_id="O2" value="-0.6" spread="2.9"/>
                    <measurement group_id="O3" value="-0.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Chloride (Week 87)</title>
        <description>Change in Chloride was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chloride (Week 87)</title>
          <description>Change in Chloride was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="3.5"/>
                    <measurement group_id="O2" value="-1.0" spread="3.0"/>
                    <measurement group_id="O3" value="-1.1" spread="3.2"/>
                    <measurement group_id="O4" value="-0.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatinine (Week 34)</title>
        <description>Change in Creatinine was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine (Week 34)</title>
          <description>Change in Creatinine was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="9.4"/>
                    <measurement group_id="O2" value="-2.8" spread="10.9"/>
                    <measurement group_id="O3" value="-2.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatinine (Week 87)</title>
        <description>Change in Creatinine was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine (Week 87)</title>
          <description>Change in Creatinine was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="11.9"/>
                    <measurement group_id="O2" value="-2.5" spread="11.7"/>
                    <measurement group_id="O3" value="-2.0" spread="9.8"/>
                    <measurement group_id="O4" value="1.8" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatine Kinase (Week 34)</title>
        <description>Change in Creatine kinase was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatine Kinase (Week 34)</title>
          <description>Change in Creatine kinase was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="136.6"/>
                    <measurement group_id="O2" value="10.9" spread="101.0"/>
                    <measurement group_id="O3" value="-23.5" spread="355.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatine Kinase (Week 87)</title>
        <description>Change in Creatine kinase was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatine Kinase (Week 87)</title>
          <description>Change in Creatine kinase was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.7" spread="1603.3"/>
                    <measurement group_id="O2" value="-9.4" spread="411.3"/>
                    <measurement group_id="O3" value="1.3" spread="89.3"/>
                    <measurement group_id="O4" value="30.5" spread="125.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gamma-glutamyl Transferase (GGT) (Week 34)</title>
        <description>Change in GGT was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gamma-glutamyl Transferase (GGT) (Week 34)</title>
          <description>Change in GGT was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="66.2"/>
                    <measurement group_id="O2" value="-5.8" spread="17.0"/>
                    <measurement group_id="O3" value="-4.2" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gamma-glutamyl Transferase (GGT) (Week 87)</title>
        <description>Change in GGT was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gamma-glutamyl Transferase (GGT) (Week 87)</title>
          <description>Change in GGT was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="16.4"/>
                    <measurement group_id="O2" value="29.3" spread="39.3"/>
                    <measurement group_id="O3" value="25.9" spread="23.8"/>
                    <measurement group_id="O4" value="20.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Phosphate (Inorganic) (Week 34)</title>
        <description>Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Phosphate (Inorganic) (Week 34)</title>
          <description>Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" spread="0.183"/>
                    <measurement group_id="O2" value="0.155" spread="0.182"/>
                    <measurement group_id="O3" value="0.181" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Phosphate (Inorganic)(Week 87)</title>
        <description>Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Phosphate (Inorganic)(Week 87)</title>
          <description>Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" spread="0.190"/>
                    <measurement group_id="O2" value="0.125" spread="0.193"/>
                    <measurement group_id="O3" value="0.076" spread="0.190"/>
                    <measurement group_id="O4" value="0.115" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Potassium (Week 34)</title>
        <description>Change in Potassium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Potassium (Week 34)</title>
          <description>Change in Potassium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.44"/>
                    <measurement group_id="O2" value="-0.06" spread="0.39"/>
                    <measurement group_id="O3" value="0.04" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Potassium (Week 87)</title>
        <description>Change in Potassium was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Potassium (Week 87)</title>
          <description>Change in Potassium was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.45"/>
                    <measurement group_id="O2" value="0.00" spread="0.44"/>
                    <measurement group_id="O3" value="-0.00" spread="0.40"/>
                    <measurement group_id="O4" value="-0.03" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sodium (Week 34)</title>
        <description>Change in Sodium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sodium (Week 34)</title>
          <description>Change in Sodium was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.4"/>
                    <measurement group_id="O2" value="0.1" spread="2.9"/>
                    <measurement group_id="O3" value="0.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sodium (Week 87)</title>
        <description>Change in Sodium was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sodium (Week 87)</title>
          <description>Change in Sodium was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.35"/>
                    <measurement group_id="O2" value="0.0" spread="2.92"/>
                    <measurement group_id="O3" value="-0.3" spread="2.74"/>
                    <measurement group_id="O4" value="0.5" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Protein (Week 34)</title>
        <description>Change in total protein was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Protein (Week 34)</title>
          <description>Change in total protein was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="5.48"/>
                    <measurement group_id="O2" value="-0.97" spread="4.36"/>
                    <measurement group_id="O3" value="-0.83" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Protein (Week 87)</title>
        <description>Change in total protein was measured from baseline (week -3) until the end of extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Protein (Week 87)</title>
          <description>Change in total protein was measured from baseline (week -3) until the end of extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="5.17"/>
                    <measurement group_id="O2" value="-0.74" spread="4.88"/>
                    <measurement group_id="O3" value="-1.31" spread="4.91"/>
                    <measurement group_id="O4" value="-1.59" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urea (Week 34)</title>
        <description>Change in Urea was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urea (Week 34)</title>
          <description>Change in Urea was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.27"/>
                    <measurement group_id="O2" value="-0.40" spread="1.16"/>
                    <measurement group_id="O3" value="-0.19" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urea (Week 87)</title>
        <description>Change in Urea was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urea (Week 87)</title>
          <description>Change in Urea was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="1.40"/>
                    <measurement group_id="O2" value="-0.21" spread="1.28"/>
                    <measurement group_id="O3" value="-0.26" spread="1.35"/>
                    <measurement group_id="O4" value="-0.03" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Uric Acid (Week 34)</title>
        <description>Change in Uric acid was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid (Week 34)</title>
          <description>Change in Uric acid was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.228" spread="52.557"/>
                    <measurement group_id="O2" value="-12.61" spread="50.534"/>
                    <measurement group_id="O3" value="-21.11" spread="57.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Uric Acid (Week 87)</title>
        <description>Change in Uric acid was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid (Week 87)</title>
          <description>Change in Uric acid was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.22" spread="59.042"/>
                    <measurement group_id="O2" value="-21.95" spread="58.903"/>
                    <measurement group_id="O3" value="-18.02" spread="59.716"/>
                    <measurement group_id="O4" value="-31.31" spread="86.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration Rate (GFR) Creatinine (CKD-EPI) (Week 34)</title>
        <description>Change in Estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Glomerular Filtration Rate (GFR) Creatinine (CKD-EPI) (Week 34)</title>
          <description>Change in Estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="10.68"/>
                    <measurement group_id="O2" value="2.77" spread="10.07"/>
                    <measurement group_id="O3" value="2.57" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated GFR Creatinine (CKD-EPI) (Week 87)</title>
        <description>Change in estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated GFR Creatinine (CKD-EPI) (Week 87)</title>
          <description>Change in estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="12.67"/>
                    <measurement group_id="O2" value="2.38" spread="12.28"/>
                    <measurement group_id="O3" value="1.44" spread="10.52"/>
                    <measurement group_id="O4" value="1.67" spread="15.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (Week 34)</title>
        <description>Change in Fasting plasma glucosewas measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (Week 34)</title>
          <description>Change in Fasting plasma glucosewas measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.42"/>
                    <measurement group_id="O2" value="0.12" spread="0.65"/>
                    <measurement group_id="O3" value="0.00" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (Week 87)</title>
        <description>Change in Fasting plasma glucose was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (Week 87)</title>
          <description>Change in Fasting plasma glucose was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.46"/>
                    <measurement group_id="O2" value="0.13" spread="0.77"/>
                    <measurement group_id="O3" value="0.05" spread="0.68"/>
                    <measurement group_id="O4" value="0.04" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin (Week 34)</title>
        <description>Change in Fasting insulin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin (Week 34)</title>
          <description>Change in Fasting insulin was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.563" spread="45.217"/>
                    <measurement group_id="O2" value="27.580" spread="76.230"/>
                    <measurement group_id="O3" value="12.778" spread="53.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin (Week 87)</title>
        <description>Change in Fasting insulin was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin (Week 87)</title>
          <description>Change in Fasting insulin was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="57.31"/>
                    <measurement group_id="O2" value="-3.7" spread="62.39"/>
                    <measurement group_id="O3" value="-6.5" spread="53.67"/>
                    <measurement group_id="O4" value="13.4" spread="54.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Steady State Beta Cell Function (%B) (Week 34)</title>
        <description>Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Steady State Beta Cell Function (%B) (Week 34)</title>
          <description>Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of beta cell function</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.10" spread="105.45"/>
                    <measurement group_id="O2" value="36.26" spread="290.00"/>
                    <measurement group_id="O3" value="54.90" spread="173.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Steady State Beta Cell Function (%B) (Week 87)</title>
        <description>Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the week 87.</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Steady State Beta Cell Function (%B) (Week 87)</title>
          <description>Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the week 87.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of beta cell function</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.72" spread="154.22"/>
                    <measurement group_id="O2" value="-16.54" spread="148.72"/>
                    <measurement group_id="O3" value="-7.34" spread="97.62"/>
                    <measurement group_id="O4" value="34.54" spread="161.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance (IR %) (Week 34)</title>
        <description>Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance (IR %) (Week 34)</title>
          <description>Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of insulin resistance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.76"/>
                    <measurement group_id="O2" value="1.26" spread="3.42"/>
                    <measurement group_id="O3" value="0.47" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance (IR %) (Week 87)</title>
        <description>Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance (IR %) (Week 87)</title>
          <description>Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of insulin resistance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="2.17"/>
                    <measurement group_id="O2" value="-0.06" spread="3.14"/>
                    <measurement group_id="O3" value="-0.02" spread="1.99"/>
                    <measurement group_id="O4" value="0.52" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycated Haemoglobin (HbA1c) (%) (Week 34)</title>
        <description>Change in Glycated haemoglobin (HbA1c) (%) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
        <time_frame>Week -3, week 34</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Norditropin</title>
            <description>Participants recieved Norditropin® FlexPro® 10 mg/1.5 mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Somapacitan</title>
            <description>Participants received Somapacitan PDS290 10mg/1.5mL for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycated Haemoglobin (HbA1c) (%) (Week 34)</title>
          <description>Change in Glycated haemoglobin (HbA1c) (%) was measured from baseline (week -3) until the end of the main treatment period (week 34).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.37"/>
                    <measurement group_id="O2" value="0.09" spread="0.26"/>
                    <measurement group_id="O3" value="0.09" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycated Haemoglobin (HbA1c) (%) (Week 87)</title>
        <description>Change in Glycated haemoglobin (HbA1c) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
        <time_frame>week -3, week 87</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Somapacitan</title>
            <description>Participants who received placebo in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Somapacitan/Somapacitan</title>
            <description>Participants who received somapacitan in the main period, continued to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O3">
            <title>Norditropin/Norditropin</title>
            <description>Participants who received Norditropin in the main period, continued to receive Norditropin for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
          <group group_id="O4">
            <title>Norditropin/Somapacitan</title>
            <description>Participants who received Norditropin in the main period, were switched to receive somapacitan for 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment) in the extension period of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycated Haemoglobin (HbA1c) (%) (Week 87)</title>
          <description>Change in Glycated haemoglobin (HbA1c) was measured from baseline (week -3) until the end of the extension treatment period (week 87).</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.26"/>
                    <measurement group_id="O2" value="0.11" spread="0.37"/>
                    <measurement group_id="O3" value="0.10" spread="0.28"/>
                    <measurement group_id="O4" value="0.07" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 0-88</time_frame>
      <desc>All presented AEs are TEAEs. A treatment-emergent AE (TEAE) was defined as an event with onset after first study medicine administration. The results are based on the safety analysis set which included all randomised participants who received at least one dose of trial product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Main Phase</title>
          <description>Participants received placebo for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="E2">
          <title>Somapacitan - Main Phase</title>
          <description>Participants received somapacitan for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="E3">
          <title>Norditropin - Main Phase</title>
          <description>Participants received Norditropin® for 34 weeks (8 weeks dose titration followed by 26 weeks fixed dose treatment) in the main phase of the trial.</description>
        </group>
        <group group_id="E4">
          <title>Somapacitan - Extension Phase</title>
          <description>The extension phase treatment period was 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment). This reporting group shows data from the extension phase for the following listed participants: 1) participants who received placebo in the main phase, and switched to receive somapacitan in the extension phase. 2) Participants who received somapacitan in the main phase were continued to receive somapacitan in the extension phase. 3) Participants who received Norditropin® in the main phase and re-randomised at the end of the main phase to receive somapacitan in the extension phase (randomisation was done in a 1:1 manner to receive either somapacitan and Norditropin®).</description>
        </group>
        <group group_id="E5">
          <title>Norditropin- Extension Phase</title>
          <description>The extension phase treatment period was 52 weeks (8 weeks dose titration followed by 44 weeks fixed dose treatment). This reporting group shows data from the extension phase for the participants who received Norditropin® in the main phase and re-randomised at the end of the main phase to receive Norditropin® in the extension phase (randomisation was done in a 1:1 manner to receive either somapacitan and Norditropin®).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoconcentration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Secondary adrenocortical insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug dispensing error</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood testosterone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cholangiogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E4" events="21" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" events="14" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" events="17" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E4" events="41" subjects_affected="33" subjects_at_risk="220"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="220"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E2" events="45" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="50" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E4" events="48" subjects_affected="25" subjects_at_risk="220"/>
                <counts group_id="E5" events="23" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Reporting Anchor and Disclosure (1452)</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <phone>(+1) 866-867-7178</phone>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02229851
org study id: NN8640-4054
secondary id: 2013-002892-16
secondary id: U1111-1145-0211
secondary id: JapicCTI-152767
nct id: NCT02229851
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly
      dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin
      (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone
      deficiency.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Investigator)
measure: Change in Truncal Fat Percentage (Week 34)
time frame: Week -3, week 34
description: Change in Truncal fat percentage was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Truncal Fat Percentage (Week 87)
time frame: week -3, week 87
description: Change in Truncal fat percentage was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Truncal Fat Mass (Week 34)
time frame: Week -3, week 34
description: Change in Truncal fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Truncal Fat Mass (Week 87)
time frame: week -3, week 87
description: Change in Truncal fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Truncal Lean Body Mass (Week 34)
time frame: Week -3, week 34
description: Change in Truncal lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Truncal Lean Body Mass (Week 87)
time frame: week -3, week 87
description: Change in Truncal lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Total Fat Mass (Week 34)
time frame: Week -3, week 34
description: Change in Total fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Total Fat Mass (Week 87)
time frame: Week -3, week 87
description: Change in total fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Visceral Adipose Tissue (Week 34)
time frame: Week -3, week 34
description: Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Visceral Adipose Tissue (Week 87)
time frame: Week -3, week 87
description: Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Android Fat Mass (Week 34)
time frame: Week -3, week 34
description: Change in Android fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Android Fat Mass (Week 87)
time frame: week -3, week 87
description: Change in Android fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Gynoid Fat Mass (Week 34)
time frame: Week -3, week 34
description: Change in Gynoid fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Gynoid Fat Mass (Week 87)
time frame: week -3, week 87
description: Change in Gynoid fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Appendicular Skeletal Muscle Mass (Week 34)
time frame: Week -3, week 34
description: Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Appendicular Skeletal Muscle Mass (Week 87)
time frame: week -3, week 87
description: Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Lean Body Mass (Week 34)
time frame: Week -3, week 34
description: Change in Lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Lean Body Mass (Week 87)
time frame: week -3, week 87
description: Change in Lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Bone Mineral Content (Week 87)
time frame: week -3, week 87
description: Change in Bone mineral content was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Bone Mineral Density (Week 87)
time frame: week -3, week 87
description: Change in Bone mineral density was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in IGF-I SDS (Week 34)
time frame: Week -3, week 34
description: Change in insulin-like growth factor (IGF-I) standard deviation scores (SDS) was measured from baseline (week -3) until the end of the main treatment period (week 34). A higher score reflects a better outcome.
measure: Change in IGF-I SDS (Week 87)
time frame: Week -3, week 87
description: Change in IGF-I SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87). A higher score reflects a better outcome.
measure: Change in IGFBP 3 SDS (Week 34)
time frame: Week -3, week 34
description: Change in insulin like growth factor binding protein 3 (IGFBP 3) SDS was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in IGFBP 3 SDS (Week 87)
time frame: Week -3, week 87
description: Change in IGFBP 3 SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in TRIM-AGHD (Total and Domain Scores) (Week 34)
time frame: Week 0, week 34
description: Change in treatment-related impact measure - adult growth hormone deficiency (TRIM-AGHD) scores (total and domain scores) was measured from baseline (week 0) until the end of the main treatment period (week 34). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.
measure: Change in TRIM-AGHD (Total and Domain Scores) (Week 87)
time frame: week 0, week 87
description: Change in TRIM-AGHD (total and domain scores) was measured from baseline (week 0) until the end of the extension treatment period (week 87). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.
measure: Change in SF-36v2 (Summary and Domain Scores) (Week 34)
time frame: Week 0, week 34
description: SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.
measure: Change in SF-36v2 (Summary and Domain Scores) (Week 87)
time frame: week 0, week 87
description: SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.
measure: TSQM-9 Scores (Domain Scores) (Week 34)
time frame: Week 34
description: Scores from the TSQM-9 scale were calculated at the end of the main treatment period (week 34). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.
measure: TSQM-9 Scores (Domain Scores) (Week 87)
time frame: Week 87
description: Scores from the TSQM-9 scale were calculated at the end of the extension treatment period (week 87). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.
measure: Change in Total Cholesterol (Week 34)
time frame: Week -3, week 34
description: Change in Total cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Total Cholesterol (Week 87)
time frame: week -3, week 87
description: Change in Total cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in HDL-cholesterol (Week 34)
time frame: Week -3, week 34
description: Change in High-density lipoprotein (HDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in HDL-cholesterol (Week 87)
time frame: week -3, week 87
description: Change in HDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in LDL-cholesterol (Week 34)
time frame: Week -3, week 34
description: Change in Low-density lipoprotein (LDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in LDL-cholesterol (Week 87)
time frame: week -3, week 87
description: Change in LDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Triglycerides (Week 34)
time frame: Week -3, week 34
description: Change in Triglycerides was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Triglycerides (Week 87)
time frame: week -3, week 87
description: Change in Triglycerides was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Hs-CRP (Week 34)
time frame: Week -3, week 34
description: Change in high-sensitivity C-reactive protein (hs-CRP) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Hs-CRP (Week 87)
time frame: week -3, week 87
description: Change in hs-CRP was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in IL-6 (Week 34)
time frame: Week -3, week 34
description: Change in Interleukin 6 (IL-6) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in IL-6 (Week 87)
time frame: week -3, week 87
description: Change in IL-6 was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Body Weight (Week 34)
time frame: Week -3, week 34
description: Change in body weight was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Body Weight (Week 87)
time frame: week -3, week 87
description: Change in body weight was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Waist Circumference (Week 34)
time frame: Week -3, week 34
description: Change in waist circumference was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Waist Circumference (Week 87)
time frame: week -3, week 87
description: Change in waist circumference was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Number of Adverse Events (Weeks 0-35)
time frame: Weeks 0-35
description: Number of adverse events from baseline (week 0) until the end of week 35 were reported. This endpoint shows number of treatment-emergent adverse events (TEAEs), including the injection site reactions.
measure: Number of Adverse Events (Weeks 0-88)
time frame: Weeks 0-88
description: Number of adverse events from baseline (week 0) until the end of week 88 were reported. This endpoint shows the number of TEAEs along with the injection site reactions.
measure: Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-35)
time frame: Weeks 0 to 35
description: Number of participants with anti-NNC0195-0092 antibodies at week 35 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.
measure: Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-88)
time frame: Weeks 0 to 88
description: Number of participants with anti-NNC0195-0092 antibodies at week 88 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.
measure: Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-35)
time frame: Weeks 0 to 35
description: Incidence of technical complaints were recorded from baseline (week 0) until week 35.
measure: Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-88)
time frame: Weeks 0 to 88
description: Incidence of technical complaints were recorded from baseline (week 0) until week 88.
measure: Change in Physical Examination During Exposure to Trial Product (Week 35)
time frame: Week 0 and week 35
description: Change in physical examination from baseline (week 0) until the end of the main treatment period (week 35) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central & Peripheral nervous sys. 7) Skin 8) Lymph node palpation
measure: Change in Physical Examination During Exposure to Trial Product (Week 88)
time frame: Week 0 and week 88
description: Change in physical examination from baseline (week 0) until the end of the extension period (week 88) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central & Peripheral nervous sys. 7) Skin 8) Lymph node palpation
measure: Change in Electrocardiogram (ECG) Evaluation During Exposure to Trial Product (Week 35)
time frame: Week -3 and week 35
description: Change in Electrocardiogram (ECG) evaluation from baseline (week -3) until the end of the main treatment period (week 35) was reported.
measure: Change in ECG Evaluation During Exposure to Trial Product (Week 88)
time frame: Week -3 and week 88
description: Change in ECG evaluation from baseline (week 0) until the end of the extension period (Week 88) was reported.
measure: Change in Diastolic Blood Pressure (Week 35)
time frame: Week -3, week 35
description: Change in diastolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).
measure: Change in Diastolic Blood Pressure (Week 88)
time frame: Week -3, week 88
description: Change in diastolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period week 88.
measure: Change in Systolic Blood Pressure (Week 35)
time frame: Week -3, week 35
description: Change in systolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).
measure: Change in Systolic Blood Pressure (Week 88)
time frame: Week -3, week 88
description: Change in systolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period (week 88).
measure: Change in Pulse (Week 35)
time frame: Week -3, week 35
description: Change in pulse was measured from baseline (week -3) until the end of the main treatment period (week 35).
measure: Change in Pulse (Week 88)
time frame: Week -3, week 88
description: Change in pulse was measured from baseline (week -3) until the end of the extension treatment period (week 88).
measure: Change in Haemoglobin (Week 34)
time frame: Week -3, week 34
description: Change in Haemoglobin was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Haemoglobin (Week 87)
time frame: week -3, week 87
description: Change in Haemoglobin was measured from baseline (week -3) until the end of the week 87.
measure: Change in Haematocrit (Week 34)
time frame: Week -3, week 34
description: Change in Haematocrit was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Haematocrit (Week 87)
time frame: week -3, week 87
description: Change in Haematocrit was measured from baseline (week -3) until the end of the week 87.
measure: Change in Erythrocytes (Week 34)
time frame: Week -3, week 34
description: Change in Erythrocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Erythrocytes (Week 87)
time frame: week -3, week 87
description: Change in Erythrocytes was measured from baseline (week -3) until the end of the week 87.
measure: Change in Mean Corpuscular Volume (MCV) (Week 34)
time frame: Week -3, week 34
description: Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Mean Corpuscular Volume (MCV) (Week 87)
time frame: week -3, week 87
description: Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the week 87.
measure: Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 34)
time frame: Week -3, week 34
description: Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 87)
time frame: week -3, week 87
description: Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the week 87.
measure: Change in Thrombocytes (Week 34)
time frame: Week -3, week 34
description: Change in Thrombocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Thrombocytes (Week 87)
time frame: week -3, week 87
description: Change in Thrombocytes was measured from baseline (week -3) until the end of the week 87.
measure: Change in Leucocytes (Week 34)
time frame: Week -3, week 34
description: Change in Leucocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Leucocytes (Week 87)
time frame: week -3, week 87
description: Change in Leucocytes was measured from baseline (week -3) until the end of the week 87.
measure: Change in Alanine Aminotransferase (ALT) (Week 34)
time frame: Week -3, week 34
description: Change in ALT was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Alanine Aminotransferase (ALT) (Week 87)
time frame: week -3, week 87
description: Change in ALT was measured from baseline (week -3) until the end of the week 87.
measure: Change in Albumin (Week 34)
time frame: Week -3, week 34
description: Change in Albumin was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Albumin (Week 87)
time frame: week -3, week 87
description: Change in Albumin was measured from baseline (week -3) until the end of the week 87.
measure: Change in Alkaline Phosphatase (ALP) (Week 34)
time frame: Week -3, week 34
description: Change in Alkaline phosphatase (ALP) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Alkaline Phosphatase (AP) (Week 87)
time frame: Week -3, week 87
description: Change in Alkaline phosphatase (AP) was measured from baseline (week -3) until the end of the week 87.
measure: Change in Aspartate Aminotransferase (AST) (Week 34)
time frame: Week -3, week 34
description: Change in AST was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Aspartate Aminotransferase (AST) (Week 87)
time frame: Week -3, week 87
description: Change in AST was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Bilirubin (Week 34)
time frame: Week -3, week 34
description: Change in Bilirubin was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Bilirubin (Week 87)
time frame: week -3, week 87
description: Change in Bilirubin was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Calcium (Week 34)
time frame: Week -3, week 34
description: Change in Calcium was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Calcium (Week 87)
time frame: week -3, week 87
description: Change in Calcium was measured from baseline (week -3) until the end of the week 87.
measure: Change in Chloride (Week 34)
time frame: Week -3, week 34
description: Change in Chloride was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Chloride (Week 87)
time frame: week -3, week 87
description: Change in Chloride was measured from baseline (week -3) until the end of the week 87.
measure: Change in Creatinine (Week 34)
time frame: Week -3, week 34
description: Change in Creatinine was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Creatinine (Week 87)
time frame: week -3, week 87
description: Change in Creatinine was measured from baseline (week -3) until the end of the week 87.
measure: Change in Creatine Kinase (Week 34)
time frame: Week -3, week 34
description: Change in Creatine kinase was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Creatine Kinase (Week 87)
time frame: week -3, week 87
description: Change in Creatine kinase was measured from baseline (week -3) until the end of the week 87.
measure: Change in Gamma-glutamyl Transferase (GGT) (Week 34)
time frame: Week -3, week 34
description: Change in GGT was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Gamma-glutamyl Transferase (GGT) (Week 87)
time frame: week -3, week 87
description: Change in GGT was measured from baseline (week -3) until the end of the week 87.
measure: Change in Phosphate (Inorganic) (Week 34)
time frame: Week -3, week 34
description: Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Phosphate (Inorganic)(Week 87)
time frame: week -3, week 87
description: Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the week 87.
measure: Change in Potassium (Week 34)
time frame: Week -3, week 34
description: Change in Potassium was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Potassium (Week 87)
time frame: week -3, week 87
description: Change in Potassium was measured from baseline (week -3) until the end of the week 87.
measure: Change in Sodium (Week 34)
time frame: Week -3, week 34
description: Change in Sodium was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Sodium (Week 87)
time frame: week -3, week 87
description: Change in Sodium was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Total Protein (Week 34)
time frame: Week -3, week 34
description: Change in total protein was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Total Protein (Week 87)
time frame: week -3, week 87
description: Change in total protein was measured from baseline (week -3) until the end of extension treatment period (week 87).
measure: Change in Urea (Week 34)
time frame: Week -3, week 34
description: Change in Urea was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Urea (Week 87)
time frame: week -3, week 87
description: Change in Urea was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Uric Acid (Week 34)
time frame: Week -3, week 34
description: Change in Uric acid was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Uric Acid (Week 87)
time frame: week -3, week 87
description: Change in Uric acid was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Estimated Glomerular Filtration Rate (GFR) Creatinine (CKD-EPI) (Week 34)
time frame: Week -3, week 34
description: Change in Estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Estimated GFR Creatinine (CKD-EPI) (Week 87)
time frame: week -3, week 87
description: Change in estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Fasting Plasma Glucose (Week 34)
time frame: Week -3, week 34
description: Change in Fasting plasma glucosewas measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Fasting Plasma Glucose (Week 87)
time frame: week -3, week 87
description: Change in Fasting plasma glucose was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Fasting Insulin (Week 34)
time frame: Week -3, week 34
description: Change in Fasting insulin was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Fasting Insulin (Week 87)
time frame: week -3, week 87
description: Change in Fasting insulin was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Steady State Beta Cell Function (%B) (Week 34)
time frame: Week -3, week 34
description: Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Steady State Beta Cell Function (%B) (Week 87)
time frame: week -3, week 87
description: Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the week 87.
measure: Change in Insulin Resistance (IR %) (Week 34)
time frame: Week -3, week 34
description: Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Insulin Resistance (IR %) (Week 87)
time frame: week -3, week 87
description: Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the extension treatment period (week 87).
measure: Change in Glycated Haemoglobin (HbA1c) (%) (Week 34)
time frame: Week -3, week 34
description: Change in Glycated haemoglobin (HbA1c) (%) was measured from baseline (week -3) until the end of the main treatment period (week 34).
measure: Change in Glycated Haemoglobin (HbA1c) (%) (Week 87)
time frame: week -3, week 87
description: Change in Glycated haemoglobin (HbA1c) was measured from baseline (week -3) until the end of the extension treatment period (week 87).
arm group label: NNC0195-0092 (somapacitan)
arm group type: Experimental
arm group label: Daily hGH
arm group type: Active Comparator
arm group label: Placebo
arm group type: Placebo Comparator
description: Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
intervention type: Drug
intervention name: somapacitan
description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
arm group label: NNC0195-0092 (somapacitan)
arm group label: Placebo
other name: NNC0195-0092
intervention type: Drug
intervention name: somatropin
description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
arm group label: Daily hGH
intervention type: Drug
intervention name: placebo
description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
arm group label: Placebo
criteria: 
gender: All
minimum age: 23 Years
maximum age: 79 Years
healthy volunteers: No
last name: Clinical Reporting Anchor and Disclosure' (1452)
role: Study Director
affiliation: Novo Nordisk A/S
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: Brazil
country: Germany
country: India
country: Israel
country: Japan
country: Latvia
country: Lithuania
country: Malaysia
country: Norway
country: Poland
country: Romania
country: Russian Federation
country: South Africa
country: Sweden
country: Turkey
country: Ukraine
country: United Kingdom
country: United States
url: http://novonordisk-trials.com
description: Clinical Trials at Novo Nordisk
citation: Johannsson G, Gordon MB, Hojby Rasmussen M, Hakonsson IH, Karges W, Svaerke C, Tahara S, Takano K, Biller BMK. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1358-76. doi: 10.1210/clinem/dgaa049.
PMID: 32022863
responsible party type: Sponsor
mesh term: Dwarfism, Pituitary
mesh term: Endocrine System Diseases
sharing ipd: Yes
ipd description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 